The value of an antibody sequence depends on what surrounds it.
ARCH is Keystone BioInsights' proprietary antibody research platform, linking sequences to their biological, functional, and clinical context.
The problem
Antibody data is spread across records that were not built to work together.
Sequence repositories are useful and well-developed, but they do not always annotate, curate, or connect sequence data to the information scientists need when making decisions about an antibody.
They also do not necessarily prioritize the antibodies and data most relevant to therapeutic discovery using traditional methods or AI.
The platform we are building
ARCH is being built to assemble antibody data from fragmented sources into a single platform.
We are starting with patents and other sources that help us identify and prioritize antibodies relevant to therapeutic discovery and development. Sequence repositories are only one of the data sources we are using to build the platform.
ARCH will prioritize and connect sequences with patent claims and disclosures, clinical records, biological and structural databases, discovery methods, functional findings, and other evidence.
The initial release is planned for 2026 and is intended to encompass all FDA-approved therapeutic antibodies. ARCH is intended as a resource for antibody discovery scientists and computational companies developing AI tools that need well-curated training data.
What makes our approach unique
ARCH is being built by scientists who know what drug discovery teams need to understand.
Our team combines hands-on experience in antibody discovery and development with expertise in bioinformatics, computational biology, and structural biology. That perspective helps us focus on the questions scientists ask about targets, mechanisms, discovery methods, function, and evidence.
Meet the teamEarly adopters
We are forming the ARCH Early Adopters Program.
Early adopters will have access to selected public and private web views of the ARCH database as new versions are released, beginning with the initial FDA-approved antibody set planned for 2026.
Early adopters will also receive priority access to custom projects that use ARCH, including projects that may not be offered more broadly while the platform is developing.